A randomized controlled trial of Ninjin yoeito in the perioperative period of lung cancer

Tanaka Yugo0 个研究点目标入组 140 人开始时间: 2020年5月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients over 20 years old with performance status of 0-1 who were diagnosed or suspected with primary lung cancer.
•2. Patients undergoing uni-lobectomy with group-2 lymphadenectomy.
•3. Patients who consented to the study in writing.
•4. Patients scheduled to undergo thoracoscopic surgery including robot-assisted surgery.

•1. Patients who have history of allergies in NINJIN-YOUEI-TO in the past.
•2. Patients who were treated with Kampo formulation for this symptom within 2 weeks before the start of this study.
•3. Patients who have severe anorexia, nausea and vomiting which are careful administration of this drug.
•4. Patients whom the doctor judged unsuitable as the subject.
•5. Patients who do not retain liver function and kidney function
•-Total Bilirubin <=2.0mg/dL
•-Serum creatinine <=2.0mg/dL
•6. Patients with conversion to open thoracotomy.
•7. Patients with pulmonary resection range of 2 or more lobes.
•8. Patients who cannot drink water within 3 days after surgery.

发起方

Tanaka Yugo